Kohima News Paper

Shigellosis Market: Industry Analysis, Treatment, Key Companies, Pipeline therapies and Forecast 2030 by DelveInsight

 Breaking News
  • No posts were found

Shigellosis Market: Industry Analysis, Treatment, Key Companies, Pipeline therapies and Forecast 2030 by DelveInsight

April 12
19:05 2021
Shigellosis Market: Industry Analysis, Treatment, Key Companies, Pipeline therapies and Forecast 2030 by DelveInsight

Shigellosis Market

Shigellosis is a major global health problem and the main sign of Shigella infection is diarrhea, which often is bloody. In addition to this, symptoms of shigellosis may include fever, as well as stomach pain.

People who have shigellosis usually get better without antibiotic treatment in 5 to 7 days. People with mild shigellosis may need only fluids and rest. Healthcare providers may prescribe antibiotics to people with severe cases of shigellosis to help them get better faster. However, some antibiotics are not effective against certain types of Shigella. Severe cases might require hospitalization so that fluids containing salts can be given intravenously and complications can be treated. Healthcare providers can also order laboratory tests to determine which antibiotics are likely to work.


Get FREE sample copy at:


DelveInsight’s “Shigellosis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Shigellosis, historical and forecasted epidemiology as well as the Shigellosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Shigellosis market report also covers emerging drugs, current treatment practices, Shigellosis market size and share of the individual therapies, current and forecasted Shigellosis Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Shigellosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 


Shigellosis Market Key Facts

  • According to the California Department of Public health (US), Shigella causes approximately 450,000 cases of diarrhea in the United States annually. Shigella germs are very contagious and can spread easily from person to person.
  • In a study of travel-associated enteric infections by Kendall et al. (2012), it was shown that in the United States, Shigella was the third most common bacterial pathogen isolated by clinical laboratories. However, these laboratories did not test for enterotoxigenic Escherichia coli, a common cause of travelers’ diarrhea.
  • As per the data by the Centers for Disease Control and Prevention (CDC), Children younger than 5 years (1-5) are most likely to get shigellosis, but people from all age groups can get this disease. Also, Shigella bacteria can cause more severe illness in infants, the elderly, or people with immune systems weakened by cancer, cancer treatments, or other serious conditions.


Get FREE sample copy at:


Key Benefits of Shigellosis Market Report

  • Shigellosis market report provides an in-depth analysis of Shigellosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The Shigellosis market report will help in developing business strategies by understanding the Shigellosis Market trends & developments, key players, and future market competition that will shape and drive the Shigellosis market in the upcoming years.
  • The Shigellosis market report covers Shigellosis market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Shigellosis patient populationmarket drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Shigellosis Market

Shigellosis Market Size is anticipated to increase during the forecast period owing to the already prescribed products along with the launch of emerging therapies in the coming years. The key driver for the surge in market size would be the direct consequences of rise in the number of incident cases.

The Shigellosis market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Shigellosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

The report gives a thorough detail of Shigellosis market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 


Get FREE sample copy at:


Shigellosis Drugs Uptake and Key Market Players

The Shigellosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Shigellosis market or expected to get launched in the market during the study period. The analysis covers Shigellosis market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


The dynamics of Shigellosis market is anticipated to change in the coming years owing to the increase in the initiatives towards control of drug-resistance, emergence of new candidates for the management of this situation during the forecast period.

Shigellosis Companies:

  • LimmaTech Biologics AG
  • GlaxoSmithKline
  • Immuron
  • Eveliqure Biotechnologies
  • And many others.


Shigellosis Therapies covered in the report include:

  • Shigella4V
  • GSK4069327A
  • Travelan/IMM-124E
  • ShigETEC
  • And many more.


Get FREE sample copy at:


Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Shigellosis Competitive Intelligence Analysis
  4. Shigellosis Market Overview at a Glance
  5. Shigellosis Disease Background and Overview
  6. Shigellosis Patient Journey
  7. Shigellosis Epidemiology and Patient Population
  8. Shigellosis Treatment Algorithm, Current Treatment, and Medical Practices
  9. Shigellosis Unmet Needs
  10. Key Endpoints of Shigellosis Treatment
  11. Shigellosis Marketed Products
  12. Shigellosis Emerging Therapies
  13. Shigellosis Seven Major Market Analysis
  14. Attribute Analysis
  15. Shigellosis Market Outlook (7 major markets)
  16. Shigellosis Access and Reimbursement Overview
  17. KOL Views on the Shigellosis Market.
  18. Shigellosis Market Drivers
  19. Shigellosis Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/shigellosis-market